Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Multicenter evaluation of a fully automated high-throughput SARS-CoV-2 antigen immunoassay

Dominik Nörz, Flaminia Olearo, Stojan Perisic, Matthias Bauer, Elena Riester, Tanja Schneider, Kathrin Schönfeld, Tina Laengin, Marc Lütgehetmann
doi: https://doi.org/10.1101/2021.04.09.21255047
Dominik Nörz
1Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flaminia Olearo
1Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stojan Perisic
2Hospital of Stuttgart, Institute for Clinical Chemistry and Laboratory Medicine, Stuttgart, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Bauer
3Hospital of Ludwigshafen, Institute for Laboratory Medicine, Ludwigshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Riester
4Labor Augsburg MVZ GmbH, Augsburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanja Schneider
5Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin Schönfeld
5Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Laengin
5Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lütgehetmann
1Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mluetgeh@uke.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

1 Abstract

Background Molecular testing for SARS-CoV-2 continues to suffer from delays and shortages. Antigen tests have recently emerged as a viable alternative to detect patients with high viral loads, associated with elevated risk of transmission. While rapid lateral flow tests greatly improved accessibility of SARS-CoV-2 detection in critical areas, their manual nature limits scalability and suitability for large-scale testing schemes. The Elecsys® SARS-CoV-2 Antigen assay allows antigen immunoassays to be carried out on fully automated high-throughput serology platforms.

Methods A total of 3139 nasopharyngeal and oropharyngeal swabs were collected at 3 different testing sites in Germany. Swab samples were pre-characterized by RT-qPCR and consecutively subjected to the antigen immunoassay on either the cobas e411 or cobas e801 analyzers.

Results Of the tested respiratory samples, 392 were PCR positive for SARS-CoV-2 RNA. Median concentration was 2.95×104 (interquartile range [IQR] 5.1×102—3.5×106) copies/mL. Overall sensitivity and specificity of the antigen immunoassay were 60.5% (95% confidence interval [CI] 55.5–65.4) and 99.9% (95% CI 99.6–100), respectively. A 93.7% (95% CI 89.7–96.5) sensitivity was achieved at a viral RNA concentration ≥104 copies/mL (∼cycle threshold (Ct) value<29.9).

Conclusion The Elecsys SARS-CoV-2 Antigen assay reliably detected patient samples with viral loads of 10,000 copies/mL and higher. It thus represents a viable high-throughput alternative for pre-screening of patients, or in situations where PCR testing is not readily available.

Competing Interest Statement

Tanja Schneider, Kathrin Schönfeld, and Tina Laengin are employees of Roche Diagnostics GmbH. Marc Lütgehetmann has received speaker's honoraria and related travel expenses from Roche Diagnostics. Elena Riester has received speaker's honorarium from Roche. Stojan Perisic, Flaminia Olearo, Matthias F. Bauer and Dominik Nörz have no conflicts to report. This study was funded by Roche Diagnostics GmbH (Mannheim, Germany). Medical writing support, under the direction of the authors, was provided by Tina Patrick (Elements Communications Ltd, Westerham, Kent, UK) and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland.

Funding Statement

This study was funded by Roche Diagnostics GmbH (Mannheim, Germany). Medical writing support, under the direction of the authors, was provided by Tina Patrick (Elements Communications Ltd, Westerham, Kent, UK) and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was conducted in accordance with applicable regulations, the study protocol provided by Roche Diagnostics, and the principles of the Declaration of Helsinki. The use of anonymized remnant samples material was approved by ethical review committees prior to study initiation (ethics committee names and approval numbers: Ethik-Kommission bei der Landesärztekammer Baden-Württemberg; F-2020-154 [Stuttgart]; Ethik-Kommission der Ärztekammer Hamburg: WF-184/20 [Hamburg]; Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz: 2020-15449[Ludwigshafen]).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here: https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm

https://vivli.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 15, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Multicenter evaluation of a fully automated high-throughput SARS-CoV-2 antigen immunoassay
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multicenter evaluation of a fully automated high-throughput SARS-CoV-2 antigen immunoassay
Dominik Nörz, Flaminia Olearo, Stojan Perisic, Matthias Bauer, Elena Riester, Tanja Schneider, Kathrin Schönfeld, Tina Laengin, Marc Lütgehetmann
medRxiv 2021.04.09.21255047; doi: https://doi.org/10.1101/2021.04.09.21255047
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Multicenter evaluation of a fully automated high-throughput SARS-CoV-2 antigen immunoassay
Dominik Nörz, Flaminia Olearo, Stojan Perisic, Matthias Bauer, Elena Riester, Tanja Schneider, Kathrin Schönfeld, Tina Laengin, Marc Lütgehetmann
medRxiv 2021.04.09.21255047; doi: https://doi.org/10.1101/2021.04.09.21255047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8794)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10575)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1762)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)